RE:RE:RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyDid I mention that Big Pharma sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion? They are wishing to acquire "good value" at a lower value than they are worth.
And the list of Big Pharma companies looking to hit their M&A "sweet spot" of US$5 Billion to US$25 Billion is growing, particularly given the regulatory environment presented by the FTC rulings.
Note also that the FTC announced that it will be reviewing the merger of the PGA and LIV Golf with the intent of overturning the deal.
So Pfizer's US$43 Billion acquistion of Seagen will likely be overturned and Pfizer may very well be turning to acquiring ONCY for between US$10 and US$15 Billion which would not undergo FTC scrutiny.